Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Arcus Biosciences Inc (NYSE: RCUS) closed the day trading at $21.69 down -0.37% from the previous closing price of $21.77. In other words, the price has decreased by -$0.37 from its previous closing price. On the day, 1.55 million shares were traded. RCUS stock price reached its highest trading level at $21.88 during the session, while it also had its lowest trading level at $21.252.
Ratios:
For a better understanding of RCUS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.65. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In the most recent recommendation for the company, H.C. Wainwright on February 26, 2025, Upgraded its rating to Buy and sets its target price to $24 from $18 previously.
On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.Wells Fargo initiated its Overweight rating on October 08, 2024, with a $29 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 05 ’26 when Juan Jaen bought 31,823 shares for $21.77 per share.
Goeltz II Robert C. sold 6,552 shares of RCUS for $153,186 on Dec 31 ’25. The Chief Financial Officer now owns 67,924 shares after completing the transaction at $23.38 per share. On Dec 31 ’25, another insider, Robert C. Goeltz II, who serves as the Officer of the company, bought 6,552 shares for $23.38 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 2683672064 and an Enterprise Value of 1642946048. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.18 while its Price-to-Book (P/B) ratio in mrq is 5.33. Its current Enterprise Value per Revenue stands at 6.846 whereas that against EBITDA is -4.501.
Stock Price History:
The Beta on a monthly basis for RCUS is 0.85, which has changed by 0.45911527 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $26.40, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is -2.09%, while the 200-Day Moving Average is calculated to be 65.15%.
Shares Statistics:
Over the past 3-months, RCUS traded about 1.88M shares per day on average, while over the past 10 days, RCUS traded about 1576610 shares per day. A total of 107.10M shares are outstanding, with a floating share count of 81.35M. Insiders hold about 34.25% of the company’s shares, while institutions hold 53.14% stake in the company. Shares short for RCUS as of 1765756800 were 7830605 with a Short Ratio of 4.17, compared to 1763078400 on 9888340. Therefore, it implies a Short% of Shares Outstanding of 7830605 and a Short% of Float of 9.0100005.
Earnings Estimates
. The current rating of Arcus Biosciences Inc (RCUS) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.01, with high estimates of -$0.79 and low estimates of -$1.18.
Analysts are recommending an EPS of between -$3.48 and -$3.52 for the fiscal current year, implying an average EPS of -$3.5. EPS for the following year is -$3.87, with 4.0 analysts recommending between -$3.54 and -$4.13.
Revenue Estimates
8 analysts predict $24.81M in revenue. The current quarter. It ranges from a high estimate of $40M to a low estimate of $16M. As of. The current estimate, Arcus Biosciences Inc’s year-ago sales were $36MFor the next quarter, 8 analysts are estimating revenue of $30.28M. There is a high estimate of $55M for the next quarter, whereas the lowest estimate is $16M.
A total of 10 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $254M, while the lowest revenue estimate was $229M, resulting in an average revenue estimate of $237.5M. In the same quarter a year ago, actual revenue was $258MBased on 10 analysts’ estimates, the company’s revenue will be $118.8M in the next fiscal year. The high estimate is $225M and the low estimate is $37M.
